SCHEMBL218626

SCHEMBL218626

O=C(Nc1nc2cccc(-c3ccc(CN4CCCCC4)cc3)n2n1)C1CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 16/20 1.00
JAK1 P23458 14/20 1.00
JAK3 P52333 4/20 0.82
TYK2 P29597 3/20 0.82
STK10 O94804 1/20 0.81
ABL1 P00519 1/20 0.81
CYP1A2 P05177 1/20 0.81
CSF1R P07333 1/20 0.81
FLT1 P17948 1/20 0.81
CYP2C19 P33261 1/20 0.81
FLT4 P35916 1/20 0.81
FLT3 P36888 1/20 0.81
STAT1 P42224 1/20 0.81
IRAK1 P51617 1/20 0.81
MAPK10 P53779 1/20 0.81
KCNH2 Q12809 1/20 0.81
MERTK Q12866 1/20 0.81
AAK1 Q2M2I8 1/20 0.81
Q6ZSR9 Q6ZSR9 1/20 0.81
ADCK1 Q86TW2 1/20 0.81

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2237580 0.99 JAK2 (1.00) JAK2JAK1JAK3TYK2STK10
SCHEMBL2237614 0.91 JAK1 (1.00) JAK2JAK1JAK3TYK2STK10
SCHEMBL2239378 0.91 JAK2 (0.85) JAK2JAK1JAK3TYK2STK10
SCHEMBL18405534 0.90 JAK2 (0.84) JAK2JAK1JAK3TYK2STK10
SCHEMBL217727 0.90 JAK2 (1.00) JAK2JAK1JAK3TYK2STK10
SCHEMBL7966699 0.90 JAK1 (0.84) JAK2JAK1JAK3TYK2STK10
SCHEMBL218472 0.90 JAK1 (1.00) JAK2JAK1JAK3TYK2STK10
SCHEMBL7960554 0.90 JAK2 (0.84) JAK2JAK1JAK3TYK2STK10
SCHEMBL2240163 0.90 JAK2 (1.00) JAK2JAK1JAK3TYK2STK10
SCHEMBL18397544 0.89 JAK1 (0.86) JAK2JAK1JAK3TYK2STK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10206907-B2 Compounds useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2019-02-19 US claimed
US-9415037-B2 Compounds useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2016-08-16 US claimed
US-20150150856-A1 NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES ALFASIGMA S.P.A. (IT) 2015-06-04 US claimed
US-8853240-B2 Compounds useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2014-10-07 US claimed
EP-2361251-B1 NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS NV (BE) 2014-04-30 EP claimed
US-12558360-B2 Compound useful for the treatment of degenerative and inflammatory diseases ALFASIGMA S.P.A. (IT) 2026-02-24 US disclosed
US-20240325405-A1 COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES ALFASIGMA S.P.A. (IT) 2024-10-03 US disclosed
US-12042498-B2 Compound useful for the treatment of degenerative and inflammatory diseases ALFASIGMA S.P.A. (IT) 2024-07-23 US disclosed
US-20210369727-A1 NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES ALFASIGMA S.P.A. (IT) 2021-12-02 US disclosed
US-20210369727-A1 NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES ALFASIGMA S.P.A. (IT) 2021-12-02 US disclosed
US-11000528-B2 Compound useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2021-05-11 US disclosed
US-11000528-B2 Compound useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2021-05-11 US disclosed
US-20110190260-A1 NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES ALFASIGMA S.P.A. (IT) 2011-08-04 US disclosed
US-20110190260-A1 NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES ALFASIGMA S.P.A. (IT) 2011-08-04 US disclosed
US-20110190260-A1 NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES ALFASIGMA S.P.A. (IT) 2011-08-04 US disclosed
US-20100331319-A1 NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES ALFASIGMA S.P.A. (IT) 2010-12-30 US disclosed
US-20100331319-A1 NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES ALFASIGMA S.P.A. (IT) 2010-12-30 US disclosed
US-20100331319-A1 NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES ALFASIGMA S.P.A. (IT) 2010-12-30 US disclosed
WO-2010149769-A1 5-PHENYL-[1,2,4 ]TRIAZOLO[1,5-A]PYRIDIN-2-YL CARBOXAMIDES AS JAK INHIBITORS GALAPAGOS NV (BE) 2010-12-29 WO disclosed
WO-2010010190-A1 NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS NV (BE) 2010-01-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240325405-A1 COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES IL6, BMP6, JAK1 JAK2 5/4885JAK1 3/4885JAK3 8/4885
US-20150150856-A1 NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES TLR6, TRAF6, BMP6 JAK2 242/4885JAK1 100/4885JAK3 211/4885
US-12558360-B2 Compound useful for the treatment of degenerative and inflammatory diseases JAK1, IL6, STAT3 JAK2 8/4885JAK1 1/4885JAK3 7/4885
US-10206907-B2 Compounds useful for the treatment of degenerative and inflammatory diseases TRAF6, TLR6, IL6 JAK2 222/4885JAK1 115/4885JAK3 277/4885
US-20100331319-A1 NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES IL6, JAK1, BMP6 JAK2 9/4885JAK1 2/4885JAK3 6/4885
US-20110190260-A1 NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES TRAF6, IL6, TLR6 JAK2 174/4885JAK1 84/4885JAK3 209/4885
US-12042498-B2 Compound useful for the treatment of degenerative and inflammatory diseases IL6, JAK1, BMP6 JAK2 5/4885JAK1 2/4885JAK3 9/4885
US-20210369727-A1 NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES IL6, JAK1, BMP6 JAK2 9/4885JAK1 2/4885JAK3 6/4885
US-11000528-B2 Compound useful for the treatment of degenerative and inflammatory diseases IL6, JAK1, BMP6 JAK2 5/4885JAK1 2/4885JAK3 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.